February 8, 2023 01:22 PM EST
Pharma
Manufacturing

As­traZeneca moves for­ward with a $360M API plant in Ire­land

Tyler Patchen

News Reporter

As­traZeneca’s ap­pli­ca­tion for a $360 mil­lion man­u­fac­tur­ing site in a Dublin sub­urb is yet to be ac­cept­ed, but it is mak­ing progress.

The fa­cil­i­ty, which …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Up­dat­ed: White House threat­ens ‘most fa­vored na­tion’ plan to low­er US drug prices, but many ques­tions re­main

Phar­ma in­vestors brush off Trump’s ‘most fa­vored na­tion’ plan as stocks rise

Watch Post-Hoc Live: Trump's 'most fa­vored na­tion' plan to cut drug prices

Bris­tol My­ers CEO says Amer­i­ca’s bio­phar­ma pole po­si­tion is not guar­an­teed

GSK to pay $1.2B up­front to snag Boston Phar­ma’s mid-stage MASH hope

It's been three months with­out a biotech IPO

A service from the Financial Times